Page 34 Volume 11, Número 3, 2003

Dor (2003) 11
necessário conhecer a dose prévia para
Tabela 2. Doses equianalgésicas de opióides estabelecer a farmacoequivalência entre
Opióide Parentérica Oral opióides (Tabela 2).
Morfina 10 mg 30 mg Bibliografia
Buprenorfina 0,3 mg 0,4 mg
Hidromorfona 1,5 mg 7,5 mg 1. Budd K. Buprenorphine: a review. Em: Hayward Medical Commu-
Metadona 10 mg 20 mg nications (ed). Evidence Based Medicine in practice. Londres
Pentazocina 60 mg 180 mg 2002:1-24.
Petidina 75 mg 300 mg 2. Darland T, Heinricher MM, Grandy DK. Orphanin FG/nociceptin: a
Tramadol 80 mg 120 mg role in pain and analgesia, but so much more. Trends Neurosci
1998;21(5):215-21.
3. Lewis JW. Buprenorphine. Drug Alcohol Depend 1985;14:363-72.
*Palliative Medicine. Symptomatic and Supportive care 4. Sadée W, Rosenbaum JS, Herz A. Buprenorphine: differential inte-
for patients with Advanced Cancer and AIDS. raction with opiate receptor subtypes in vivo. J Pharmacol Exp Ther
Woodruff R (ed). Oxford University Press 1999:75. 1982;223(1):157-62.
5. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical
pharmacology of buprenorphine: celing effects at high doses. Clin
Pharmacol Ther 1994;55:569-80.
6. Budd K. Experience with partial agonists in the treatment of cancer
4. Permite resgatar pacientes que não têm pain. Em: Doyle D (ed). Opioids in the treatment of cancer pain.
International Congress & Symposium Series Nº. 146. Londres:
una resposta analgésica adequada com Royal Society of Medicine 1990:51-5
morfina (mudança de opióides). 7. Heel RC, Brogden RN, Speight TM, Avery GS. Buprenorphine: A
5. Intolerância à morfina. review of its pharmacological properties and theraputic efficacy.
Drugs 17:81-110.
6. Dor neuropática resistente 8. Zaki PA, Keith DE, Brine GA, et al. Ligand induced changes
Tratamento racional da dor oncológica. insurface of mu-opioid receptor number: relationship to G protein
activation? J Pharmacol Exp Ther 2000;292(3):1127-34.
1. Estabelecer: causa, intensidade, e função 9. McCormack K. Signal transduction in neuropathic pain, with
renal. special emphasis on the analgesic role opioids - Part II: Moving
2. Contemplar o carácter multidimensional da basic science towards a new pharmacotherapy. Pain Reviews
dor (factores psicoemocionais e espirituais). 1999;99-131.
3. Selecção do fármaco adequado, estabelecer 10. Freye E. Planificación de la terapia analgésica farmacológica en
dolor oncológico. Em: Freye E (ed). Opioide in der Medizin. 5ª ed.
via de administração e intervalo de dose. Berlim: Springer Verlag 2001:64-7.
4. Uso apropriado de fármacos adjuvantes. 11. Budd K. Buprenorphine. Clin Anaesth 1983;1:147-79.
5. Está recebendo opióides anteriormente e a 12. Benedetti F, Vighetti S, Amancio M, et al. Dose-response relati-
onship of opioids in nociceptive and neuropathic postoperative
que dose? Tem tolerância a opioides? É pain. Pain 1998;74:205-11.

DOR

34